BIOMARIN PHARMACEUTICAL INC Material Contracts
Every material contract the company filed as Exhibit 10 (executive pay plans, credit agreements, supplier and indemnity agreements), newest first, with the filing's own description.
- 2017-11-13: Form 10-Q/A; Exhibit 10.1; Description Settlement and License Agreement among BioMarin Pharmaceutical Inc., Merck & Cie and Par Pharmaceutical, Inc., dated as of April 12, 2017. Portions of this exhibit (indicated by asterisks) have been omitted pursuant to a request for confidential treatment. Omitted portions have been filed separately with the SEC..
- 2017-10-31: Form 10-Q; Exhibit 10.1; Description BioMarin Pharmaceutical Inc. Summary of Independent Director Compensation..
- 2017-08-02: Form 10-Q; Exhibit 10.1; Description Settlement and License Agreement among BioMarin Pharmaceutical Inc., Merck & Cie and Par Pharmaceutical, Inc., dated as of April 12, 2017. Portions of this exhibit (indicated by asterisks) have been omitted pursuant to a request for confidential treatment. Omitted portions have been filed separately with the SEC..
- 2017-06-12: Form 8-K; Exhibit 10.4; Description Form of Agreement Regarding Performance Compensation Award in the Form of Restricted Stock Units for the BioMarin Pharmaceutical Inc. 2017 Equity Incentive Plan..
| Filed | Form | Exhibit | Description |
|---|
| 2017-11-13 | 10-Q/A | 10.1 | Settlement and License Agreement among BioMarin Pharmaceutical Inc., Merck & Cie and Par Pharmaceutical, Inc., dated as of April 12, 2017. Portions of this exhibit (indicated by asterisks) have been omitted pursuant to a request for confidential treatment. Omitted portions have been filed separately with the SEC. |
|---|
| 2017-10-31 | 10-Q | 10.1 | BioMarin Pharmaceutical Inc. Summary of Independent Director Compensation. |
|---|
| 2017-08-02 | 10-Q | 10.1 | Settlement and License Agreement among BioMarin Pharmaceutical Inc., Merck & Cie and Par Pharmaceutical, Inc., dated as of April 12, 2017. Portions of this exhibit (indicated by asterisks) have been omitted pursuant to a request for confidential treatment. Omitted portions have been filed separately with the SEC. |
|---|
| 2017-06-12 | 8-K | 10.4 | Form of Agreement Regarding Performance Compensation Award in the Form of Restricted Stock Units for the BioMarin Pharmaceutical Inc. 2017 Equity Incentive Plan. |
|---|
| 2017-06-12 | 8-K | 10.3 | Form of Agreement Regarding Restricted Stock Units for the BioMarin Pharmaceutical Inc. 2017 Equity Incentive Plan. |
|---|
| 2017-06-12 | 8-K | 10.2 | Form of Stock Options Agreement for the BioMarin Pharmaceutical Inc. 2017 Equity Incentive Plan. |
|---|
| 2017-06-12 | 8-K | 10.1 | BioMarin Pharmaceutical Inc. 2017 Equity Incentive Plan. |
|---|
| 2017-02-27 | 10-K | 10.50 | Form of Agreement Regarding Performance Compensation Award in the Form of Restricted Stock Units for the BioMarin Pharmaceutical Inc. 2006 Share Incentive Plan. |
|---|
| 2017-02-27 | 10-K | 10.49 | Credit Agreement by and among BioMarin Pharmaceutical Inc., as the Borrower, Bank of America, N.A., as Administrative Agent, Swing Line Lender, L/C Issuer and a Lender, and the Lenders party thereto, dated as of November 29, 2016. |
|---|